- Home
- NOW vs SNY Comparison
NOW vs SNY Comparison
Compare NOW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOW | SNY |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.2B | 116.8B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | NOW | SNY |
|---|---|---|
| Price | $113.35 | $45.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 31 | 6 |
| Target Price | ★ $202.70 | $61.50 |
| AVG Volume (30 Days) | ★ 13.6M | 3.5M |
| Earning Date | 04-22-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.66% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $1,933,026,000.00 | N/A |
| Revenue This Year | $21.52 | $3.01 |
| Revenue Next Year | $18.41 | $5.80 |
| P/E Ratio | $68.19 | ★ $6.14 |
| Revenue Growth | ★ 39.02 | N/A |
| 52 Week Low | $98.00 | $43.32 |
| 52 Week High | $1,057.39 | $57.60 |
Technical Indicators
Market Signals| Indicator | NOW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 48.06 |
| Support Level | $98.59 | $45.20 |
| Resistance Level | $124.66 | $48.97 |
| Average True Range (ATR) | 4.77 | 0.70 |
| MACD | 3.22 | -0.04 |
| Stochastic Oscillator | 42.38 | 42.32 |
Price Performance
Historical ComparisonAbout NOW ServiceNow Inc.
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.